We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Asuragen Receives Certification for Gene Expression Profiling

By HospiMedica staff writers
Posted on 28 Feb 2007
Illumina, Inc. More...
(San Diego, CA, USA) and Asuragen, Inc. (Austin Texas, USA) have announced that Asuragen has successfully completed Illumina Certified Service Provider (CSPro) certification for gene expression profiling.

Asuragen is the first commercial service provider to offer Illumina gene expression profiling services. Illumina provides next-generation tools for the large-scale analysis of genetic variation and function.

"In response to customer requests, we are pleased to offer an additional choice in gene expression profiling with the Illumina platform,” said Rollie Carlson, President of Asuragen. "The work performed by Asuragen and Illumina to demonstrate proficiency in the CSPro program will assure customers quality data.”

Combined with Asuragen's sample preparation, scientists can perform gene expression profiling from low amounts of starting sample, including those traditionally used in clinical settings, such as biopsies, fine needle aspirates, etc. Data from the Illumina platform are compatible with Asuragen's Standard Service Premium and Pathways Analysis Services.

"Our commitment to quality and innovative technologies is what inspired us to become an Illumina CSPro. The Illumina platform allows us to provide solutions to the experimental needs of our customers,” said Scott Hunicke-Smith, vice president and general manager of Asuragen Services.

"Recent results from the MicroArray Quality Control project confirmed that Illumina's gene expression technology is capable of generating excellent quality and performance, and boosting the number of detected genes,” he continued.


Related Links:
Illumina
Asuragen

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Syringe Pump
SP50 Series
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.